RxDoctor Payments Data

Connie Perkins, DO

Obstetrics & Gynecology · Ronceverte, WVNPI 1891713269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $523 and has fallen 50.7% since, to $258 in 2025.

$2,608in general payments, 2019–2025

Across 151 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$452
  • Pfizer$412
  • Organon$289
  • Astellas Pharma US Inc$231
  • Amgen$198
  • Bayer$182
  • plus $845 from 12 others

What the payments were for

  • Food & beverage$2,51096%
  • Education$984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,608 in reported general payments places this provider in the 75th percentile of 172 obstetrics & gynecology providers in West Virginia.

See all obstetrics & gynecology providers in West Virginia

Medicare billing

Part B allowed, 2024
$31,897
Medicare patients
279
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated40$18,987
Estradiol213$8,425
Medroxyprogesterone Acetate79$1,498
Estradiol (Once Weekly)Estradiol19$1,437
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip57$1,096
Clobetasol Propionate33$1,039
ValacyclovirValacyclovir Hcl14$450
Alendronate Sodium14$122
Fluconazole12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$412$18,98740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 172 obstetrics & gynecology providers in West Virginia.

Other obstetrics & gynecology in Ronceverte

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →